$ALT Don't forget, AUD can likely be addressed by any GLP-1. This trial was primarily focused on getting additional datas for their Obesity and MASH programs. It also gives them a quicker path to patient if they continue (essentially low bar to market rather than congested Obesity or MASH).
It's possible that this renders neutral (or Red) day, but this is poised for steady climbing rather than one day pump and stay.
Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn.
Let's make some (more) money. Cheers!
$XBI $MDGL $AKRO $NVO
@Ilovemuffins1 @HarryScrotmmm I'm not speaking for everyone on the board and have done extremely well and you can look me up on all the BO's I have had this year alone- I'll name some for you $TERNS-$APLS-$AKRO tell me what you got?
$CRMD Quick look over at the gainers for today and I saw this grouping. How many Buyouts or deals did we have in this group? Good lord. Will $CRMD be added to that distinguished list? I think so.
For fun, the 2 picks above the screen grab was $AKRO, one below was $NUVL. $TERN? $VRNA? Some real life changes in here.
Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn.
Let's make some (more) money. Cheers!
$ORKA this reminds me of $AKRO when they did a similar offering into P3 results which were highly optimistic. They took the shares down afterwards to collect more. Good luck!
$ALT $ALT sits at ~$525M+ cash post offering, putting it on par with $ETNB and $AKRO heading into P3. While the $225M raise kills the financing risk, the execution feels defensive as if it is done out of desperation. Management accepted dilutive terms (warrants + low pricing) rather than waiting for AUD or histology data suggesting a "take the money and run" approach over confidence in a higher future valuation. ALT is now financially competitive, but the key gap remains: $AKRO and $ETNB have validated histology and fibrotic end points, while ALT is still leaning on weight loss + MRI-PDFF. Durso secured the runway, but now the data has to do the heavy lifting to offset the dilutiion. Hold tight, this would be a bumpy ride! Not a financial advice, do your own DD
@PashaGainz $AKRO buyout was expected. No one was surprised by that...not even $ALT. Can't speak for ETNB, but I think that caught folks by surpise...but they were well in the background. Poor examples Pashy.
@PashaGainz You forgot to mention $ALT has one thing that $AKRO and $ETNB didn't...a FAILED drug for one of their MASH P2b trial Primary Endpoints.
So yes, you're full of hopium. Always have been. And this isn't conviction, this is trying to save face.
Little secret, no one missed you when you were gone.
